Blue Trust Inc. Takes $88,000 Position in Exact Sciences Co. (NASDAQ:EXAS)

Blue Trust Inc. purchased a new stake in shares of Exact Sciences Co. (NASDAQ:EXASFree Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 1,292 shares of the medical research company’s stock, valued at approximately $88,000.

Other hedge funds have also modified their holdings of the company. KB Financial Partners LLC bought a new stake in shares of Exact Sciences during the second quarter valued at approximately $32,000. Wolff Wiese Magana LLC boosted its stake in Exact Sciences by 459.5% in the fourth quarter. Wolff Wiese Magana LLC now owns 414 shares of the medical research company’s stock valued at $31,000 after acquiring an additional 340 shares during the last quarter. BluePath Capital Management LLC bought a new position in Exact Sciences in the third quarter valued at approximately $33,000. Coppell Advisory Solutions LLC bought a new position in Exact Sciences in the second quarter valued at approximately $46,000. Finally, ST Germain D J Co. Inc. bought a new position in Exact Sciences in the second quarter valued at approximately $46,000. 88.82% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on EXAS. Canaccord Genuity Group reduced their price objective on shares of Exact Sciences from $100.00 to $90.00 and set a “buy” rating on the stock in a research note on Thursday, February 22nd. Wolfe Research began coverage on shares of Exact Sciences in a research note on Wednesday, December 13th. They issued an “outperform” rating and a $95.00 price objective on the stock. Benchmark raised shares of Exact Sciences from a “hold” rating to a “buy” rating and set a $91.00 price objective on the stock in a research note on Tuesday, January 2nd. William Blair reissued an “outperform” rating on shares of Exact Sciences in a research report on Thursday, February 22nd. Finally, TheStreet cut shares of Exact Sciences from a “c-” rating to a “d+” rating in a research report on Monday, February 26th. Three investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $97.44.

View Our Latest Research Report on EXAS

Insider Buying and Selling at Exact Sciences

In other Exact Sciences news, Director D Scott Coward sold 1,376 shares of Exact Sciences stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $61.43, for a total value of $84,527.68. Following the sale, the director now directly owns 41,580 shares in the company, valued at approximately $2,554,259.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other Exact Sciences news, Director D Scott Coward sold 1,376 shares of Exact Sciences stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $61.43, for a total value of $84,527.68. Following the sale, the director now directly owns 41,580 shares in the company, valued at approximately $2,554,259.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, General Counsel James Herriott sold 421 shares of the business’s stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $61.43, for a total transaction of $25,862.03. Following the transaction, the general counsel now owns 6,494 shares in the company, valued at $398,926.42. The disclosure for this sale can be found here. In the last three months, insiders have sold 69,113 shares of company stock worth $4,165,273. Insiders own 1.30% of the company’s stock.

Exact Sciences Trading Down 1.2 %

Shares of NASDAQ:EXAS opened at $72.82 on Thursday. Exact Sciences Co. has a 12 month low of $56.05 and a 12 month high of $100.77. The company has a quick ratio of 2.07, a current ratio of 2.32 and a debt-to-equity ratio of 0.74. The company’s fifty day simple moving average is $62.29 and its 200 day simple moving average is $65.12. The firm has a market cap of $13.22 billion, a price-to-earnings ratio of -63.88 and a beta of 1.25.

Exact Sciences (NASDAQ:EXASGet Free Report) last issued its quarterly earnings results on Wednesday, February 21st. The medical research company reported ($0.27) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.53) by $0.26. Exact Sciences had a negative net margin of 8.17% and a negative return on equity of 6.60%. The firm had revenue of $646.89 million for the quarter, compared to analyst estimates of $638.83 million. During the same period in the previous year, the business earned ($0.72) EPS. The company’s revenue was up 17.0% compared to the same quarter last year. As a group, research analysts forecast that Exact Sciences Co. will post -0.86 EPS for the current fiscal year.

About Exact Sciences

(Free Report)

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.

Featured Stories

Want to see what other hedge funds are holding EXAS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exact Sciences Co. (NASDAQ:EXASFree Report).

Institutional Ownership by Quarter for Exact Sciences (NASDAQ:EXAS)

Receive News & Ratings for Exact Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences and related companies with MarketBeat.com's FREE daily email newsletter.